117 related articles for article (PubMed ID: 9028739)
1. Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma.
Visscher DW; Yadrandji S; Tabaczka P; Kraut M; Sarkar FH
Diagn Mol Pathol; 1997 Feb; 6(1):64-9. PubMed ID: 9028739
[TBL] [Abstract][Full Text] [Related]
2. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Kucway R; Du W; Kamarauskiene DS; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Apr; 21(2):127-43. PubMed ID: 9209954
[TBL] [Abstract][Full Text] [Related]
4. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.
Sessa F; Solcia E; Capella C; Bonato M; Scarpa A; Zamboni G; Pellegata NS; Ranzani GN; Rickaert F; Klöppel G
Virchows Arch; 1994; 425(4):357-67. PubMed ID: 7820300
[TBL] [Abstract][Full Text] [Related]
5. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
[TBL] [Abstract][Full Text] [Related]
6. Relationship of family cancer history to the expression of p53, p21WAF-1, HER-2/neu, and K-ras mutation in pancreatic adenocarcinoma.
Dergham ST; Dugan MC; Arlauskas P; Du W; Vaitkevicius VK; Crissman JD; Sarkar FH
Int J Pancreatol; 1997 Jun; 21(3):225-34. PubMed ID: 9322121
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking.
Westra WH; Offerhaus GJ; Goodman SN; Slebos RJ; Polak M; Baas IO; Rodenhuis S; Hruban RH
Am J Surg Pathol; 1993 Mar; 17(3):213-20. PubMed ID: 8434702
[TBL] [Abstract][Full Text] [Related]
9. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of p53 and K-ras in lung carcinomas of coal miners.
Sarkar FH; Li Y; Vallyathan V
Int J Mol Med; 2001 Oct; 8(4):453-9. PubMed ID: 11562787
[TBL] [Abstract][Full Text] [Related]
11. Alteration of the p53 tumor suppressor gene and activation of c-K-ras-2 protooncogene in endometrial adenocarcinoma from Colorado.
Enomoto T; Fujita M; Inoue M; Nomura T; Shroyer KR
Am J Clin Pathol; 1995 Feb; 103(2):224-30. PubMed ID: 7856567
[TBL] [Abstract][Full Text] [Related]
12. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations.
Husgafvel-Pursiainen K; Karjalainen A; Kannio A; Anttila S; Partanen T; Ojajärvi A; Vainio H
Am J Respir Cell Mol Biol; 1999 Apr; 20(4):667-74. PubMed ID: 10100998
[TBL] [Abstract][Full Text] [Related]
15. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
16. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison.
Jones MW; Kounelis S; Hsu C; Papadaki H; Bakker A; Swalsky PA; Finkelstein SD
Int J Gynecol Pathol; 1997 Oct; 16(4):354-60. PubMed ID: 9421075
[TBL] [Abstract][Full Text] [Related]
19. Patterns of genetic alterations in pancreatic cancer: a pooled analysis.
Blanck HM; Tolbert PE; Hoppin JA
Environ Mol Mutagen; 1999; 33(2):111-22. PubMed ID: 10217065
[TBL] [Abstract][Full Text] [Related]
20. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
